PRNewsWire
15 Jun 2026, 12:47 UTC · 14w ago
Verdict
Headline leans bullish. We score ELAN +1.00 across three claims.
Score confirms the headline.
Leans bullish
From its wording — no explicit rating
+1.00strongly bullish
What the story claims
3 claims · scored −1 bearish … +1 bullish
Elanco received USDA approval for TruCan Ultra Lyme-L4, the first and only 1/2 mL combination vaccine for canine Lyme disease and leptospirosis.
More positive than 79% of claims this week
TruCan Ultra Lyme-L4 is expected to begin shipping within the next 30 days.
Continue reading
5 related stories
More positive than 99% of ticker scores this week
Scored by the NIS engine · methodology.
Top 1 mover · tap to explore
More positive than 53% of claims this week
Leptospirosis vaccination is now recognized as a 'core vaccine' per AAHA guidelines, meaning all dogs should be vaccinated regardless of lifestyle.
More positive than 53% of claims this week
Which stocks this story touches
More positive than 99% of ticker scores this week
The company received USDA approval for a first-of-its-kind combination vaccine for dogs, expanding its product portfolio.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
Seeking Alpha
2h ago
−7.6%
Price is moving against the score
$22.34 vs $24.17 close before publication (Jun 12) · not market-adjusted
ELAN chart →
